BANK VONTOBEL/PUT/NOVO NORDISK ADR B/105/0.1/20.12.24 | Market Closed - Boerse Frankfurt Warrants 14:04:16 2024-07-16 EDT | ||
| 0.132 EUR | +1.54% |
|
| Current month | +14.78% | ||
| 1 month | -8.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 0.132 | +1.54% |
| 24-07-15 | 0.13 | +4.84% |
| 24-07-12 | 0.124 | -17.33% |
| 24-07-11 | 0.15 | +12.78% |
| 24-07-10 | 0.133 | -8.90% |
Real-time Boerse Frankfurt Warrants
Last update July 16, 2024 at 02:04 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM7SE8 |
| ISIN | DE000VM7SE86 |
| Date issued | 2024-01-02 |
| Strike | 105 $ |
| Maturity | 2024-12-20 (157 Days) |
| Parity | 10 : 1 |
| Emission price | 1.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.21 € |
|---|---|
| Lowest since issue | 0.086 € |
| Spread | 0.01 € |
| Spread % | 7.04% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
956.8
DKK
Spread / Average Target
-1.36%
- Stock Market
- Warrants
- Warrant
